Clinical Trials Browser

Phase 1 × Terminated × Idarubicin × Clear all

NCT02635074 2018-05-14

Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02049801 2017-12-06

MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute